Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hai-Yan Tu
Observed names:
HAI-YAN TU,
Hai-yan Tu,
HaiYan Tu,
Tu, Hai-Yan
Institutions:
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Southern Medical University
Observed institutions:
Guangdong General Hospital,
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital,
Southern Medical University,
South China University of Technology
ORCID:
0000-0001-7125-9878
Observed ORCID:
0000-0001-7125-9878
OpenAlex ID:
A5106486045
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
2019
·
Yi-Long Wu
, Shun Lu
, et al.
·
Journal of Thoracic Oncology
·
388
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer: A Nonrandomized Controlled Trial
2024
·
Song Dong
, Zhen Wang
, et al.
·
JAMA Oncology
·
104
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases
2025
·
Mei-Mei Zheng
, Qing Zhou
, et al.
·
Nature Medicine
·
37
Redox high phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma
2024
·
Xue-Wu Wei
, Chang Lu
, et al.
·
OncoImmunology
·
30
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial
2025
·
Yang-Si Li
, Qitao Yu
, et al.
·
Journal of Thoracic Oncology
·
24
PDF
Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
2024
·
Song Dong
, Bingfa Yan
, et al.
·
JTO Clinical and Research Reports
·
13
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease
2024
·
Chang Lu
, Hong-Hong Yan
, et al.
·
Clinical Lung Cancer
·
2
PDF
Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report
2014
·
NA ZHANG
, JIN-JI YANG
, et al.
·
Oncology Letters
·
2
PDF
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibiotics
2026
·
Wei-Chi Luo
, Zi-Jian Huang
, et al.
·
Journal of Translational Medicine
·
1
OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
2024
·
John Heymach
, Noboru Yamamoto
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Other Driver Genes as Resistance Mechanisms of ALK Inhibitors in ALK-Rearranged Lung Adenocarcinoma
2024
·
Xiao-Cheng Lin
, Qian-Yu Wang
, et al.
·
Journal of Cancer Science and Clinical Therapeutics
·
1
Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.
2020
·
Chongrui Xu
, Hai-Yan Tu
, et al.
·
Journal of Clinical Oncology
·
1
Transforming the Therapeutic Landscape of HER2-Mutant NSCLC: Emerging First-Line Treatment Strategies
2026
·
Sanjay Popat
, Jon Zugazagoitia
, et al.
·
Clinical Lung Cancer
Results from a multi-center survey among physicians and patients on the acceptance of new treatment strategy with third generation of EGFR-TKI plus bispecific antibody for advanced EGFR-mutant NSCLC
2026
·
Bin Gan
, Yi Yang
, et al.
·
JTO Clinical and Research Reports
PDF
IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non–small cell lung cancer (NSCLC).
2026
·
HaiYan Tu
, Yong Wang
, et al.
·
Journal of Clinical Oncology
Implementing flexible and adapted follow-up strategies in a patient-centric, phase II trial of first-line lorlatinib for advanced ALK-positive non–small cell lung cancer (CTONG2203).
2026
·
Jia-Xin Lin
, Qing Zhou
, et al.
·
Journal of Clinical Oncology
Abstract LB307: FUS ablation induces neuroendocrine-differentiation-like phenotypes and promotes leptomeningeal metastases in lung cancer through upregulating CD36 expression
2026
·
Peng Li
, Shouheng Lin
, et al.
·
Cancer Research
First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance
2026
·
Jia-Xin Lin
, Kai Yin
, et al.
·
Lung Cancer
Effect of CD4+PD-1+CXCR6+ T cells on the response of immune checkpoint inhibitor therapy in brain metastases of NSCLC.
2025
·
Yang-Si Li
, Wenpu Lai
, et al.
·
Journal of Clinical Oncology
Molecular profiling of neoadjuvant immunochemotherapy and identification of residual cancer cells in pCR NSCLC: A single-cell analysis of CTONG 1804 clinical trial.
2025
·
SiYang Maggie Liu
, Song Dong
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
21
Citation count:
604
H-index:
6
I10-index:
6
Year
Topic
Type